What is Zacks Small Cap’s Forecast for QNRX Q1 Earnings?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Investment analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for Quoin Pharmaceuticals in a report released on Monday, March 17th. Zacks Small Cap analyst M. Marin expects that the company will earn ($0.11) per share for the quarter. The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15.

Quoin Pharmaceuticals Price Performance

QNRX stock opened at $0.29 on Wednesday. The company has a market capitalization of $1.46 million, a PE ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a 12 month low of $0.27 and a 12 month high of $1.57. The firm’s 50-day moving average is $0.36 and its 200 day moving average is $0.55.

Insider Activity

In other Quoin Pharmaceuticals news, CFO Gordon Dunn purchased 122,221 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, with a total value of $54,999.45. Following the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at $67,984.65. This represents a 423.55 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Denise P. Carter purchased 555,556 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, with a total value of $250,000.20. Following the completion of the transaction, the chief operating officer now directly owns 602,648 shares in the company, valued at $271,191.60. The trade was a 1,179.72 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 777,777 shares of company stock worth $350,000. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Altium Capital Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth $184,000. Renaissance Technologies LLC boosted its position in shares of Quoin Pharmaceuticals by 244.1% during the 4th quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after acquiring an additional 94,431 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the 4th quarter valued at about $53,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.